Daniel Pelak, 30 Year Medical Device Senior Executive, Joins Affinergy's Board of Directors.

RESEARCH TRIANGLE PARK, N.C. -- Affinergy, Inc., a Duke University spinout with a proprietary site-specific biological delivery system, announced that Daniel A. Pelak has joined its Board of Directors effective January 2006.

"Affinergy has a broad and exciting range of potential product applications in the medical device industry," said Pelak. "I am excited to help this promising company grow into its full potential by sharing my experiences and advice. Affinergy's unique technology is well positioned for growth in the rapidly growing field of combination products. The market opportunity for Affinergy is significant."

"Dan is a highly respected medical device veteran whose wealth of knowledge and contacts will be very valuable to Affinergy," said Peyton Anderson, CEO of Affinergy. "Dan shares our passion for the use of coatings to improve medical devices and enable new products to help patients. We are grateful for his commitment to join our Board and confident he will make a major contribution. Attracting someone of Dan's caliber to Affinergy's strategic team is genuinely exciting to our founders, employees, and investors."

Mr. Pelak is the CEO of IRM, Inc., a privately held medical device company that is pioneering a disruptive technology for the treatment of patients with heart disease. Prior to IRM, he was CEO of Closure Medical, which was recently acquired by Johnson & Johnson for approximately $400 million. Previously, he spent a long career at Medtronic, Inc. rising through levels of greater responsibilities in sales and marketing. He was ultimately responsible for the general management of several operating divisions at Medtronic. During his tenure at Medtronic, he was the Vice President of Cardiovascular Marketing, Vice President and General Manager Nortech, Vice President and General Manager Perfusion Systems, and Vice President and General Manager Cardiac Surgery Technologies.

About Affinergy, Inc.

Affinergy develops site-specific biological systems using biofriendly linkers that selectively adhere to proteins, drugs, cells, and biomaterial surfaces in order to kickstart biology toward an intended outcome. Affinergy is focused on developing coatings and medical devices for the orthopedic and cardiovascular markets. Affinergy's technology was patented at Duke University and the company has been incubated at Becton Dickinson's research center in Research Triangle Park. Affinergy was awarded 2005 Innovation of the Year by Frost & Sullivan in the category of Medical Device Coatings. For more information, visit www.affinergy.com or contact Peyton Anderson at [phone].